Core Viewpoint - The company has received approval from the National Medical Products Administration for its self-developed drug, JAK inhibitor, which is indicated for adult patients with intermediate or high-risk primary myelofibrosis [1] Group 1: Drug Approval and Indications - The drug, Hydrochloride Jikaxitinib Tablets (Zepuping), is approved for use in adult patients with intermediate or high-risk primary myelofibrosis and other related diseases [1] - This drug is classified as a Class 1 new drug and works by inhibiting the JAK-STAT signaling pathway to reduce inflammation and splenomegaly [1] Group 2: Clinical Trial Results - According to Phase III clinical trials, 72.3% of participants showed a reduction in spleen volume of ≥35% from baseline after 24 weeks of treatment, indicating significant therapeutic benefits [1] Group 3: Clinical Guidelines - Hydrochloride Jikaxitinib Tablets have been included in the "2024 Guidelines for the Diagnosis and Treatment of Malignant Hematological Diseases" by the Chinese Society of Clinical Oncology (CSCO) as a Class I recommendation for first-line stratified treatment of myelofibrosis [1]